NEC — applies its AI neoantigen-prediction platform to personalized vaccines (NECVAX-NEO1) and powers partners' pipelines.
NEC Bio B.V. is conducting a Phase I/II trial for NECVAX-NEO1 in solid tumors. The study evaluates the vaccine combined with PD-1/PD-L1 monoclonal antibodies in patients who have reached stable disease, partial response, or progressive disease on standard therapy.
NEC Bio B.V. is conducting a Phase I/II trial of NECVAX-NEO1, a personalized neoantigen-targeting vaccine in neoadjuvant triple-negative breast cancer. The study evaluates the vaccine's combination with standard-of-care chemotherapy and anti-PD-1 therapy, with potential post-surgical extension to assess immune response and clinical outcomes in early-stage disease.
NEC Bio B.V. is conducting a Phase I/II multicenter trial of NECVAX-NEO1 combined with PD-1/PD-L1 monoclonal antibodies in solid tumors. The study stratifies patients by response to prior checkpoint inhibitor therapy (Stable Disease/Partial Response vs. Progressive Disease), testing the vaccine's ability to rescue or sustain response in advanced settings.
NEC Bio B.V. is recruiting for a Phase I/II trial of NECVAX-NEO1, a personalized neoantigen-targeting vaccine, in neoadjuvant triple-negative breast cancer. The study evaluates the vaccine in combination with standard-of-care anti-PD-1 therapy and chemotherapy, with potential post-surgical extension.